Clinical Trial Detail

NCT ID NCT03050216
Title Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Masonic Cancer Center, University of Minnesota
Indications

acute myeloid leukemia

Therapies

ALT-803 + Cyclophosphamide + Fludarabine

Age Groups: adult senior

No variant requirements are available.